Artimplant AB's Interim Report January 1- March 31, 2004

ARTIMPLANT AB's INTERIM REPORT JANUARY 1 - MARCH 31, 2004 SEVERAL NEW REGULATORY APPROVALS AND A STRONG FINANCIAL POSITION * Artimplant's net sales for the period reached SEK 1.0 million (SEK 1.0 million) * Losses after tax was SEK 6.6 million (SEK 5.9 million), the loss per share was SEK 0.17 (SEK -0.30) * Three new CE-certificates were granted, which cleared the way for product sales in EU * Good results from the study of accelerated rehab with Artelon® Augmentation Device ACL, and in thumb joint surgery with UCL Augmentation Device * Extended test sales of Artelon® Augmentation Device ACL in the United Kingdom * The directed share issue, based on the over subscription of the December rights issue, yielded over SEK 14 millions For more information, contact: Tord Lendau, CEO, +46 31 746 5600, +46 708 369 403, tord.lendau@artimplant.se Jonas Ström, CFO, +46 31 746 5654, +46 703 016 854, jonas.strom@artimplant.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/04/27/20040427BIT00180/wkr0001.doc The full report http://www.waymaker.net/bitonline/2004/04/27/20040427BIT00180/wkr0002.pdf The full report